REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
|Articles|August 17, 2022
Daily OTC Pearl: Go-Out
Author(s)Saro Arakelians, PharmD
Advertisement
OTC/Lifestyle Pearl of the Day: Go-Out
Indication: Go-Out is a natural supplement that treats high uric acid levels.
Insight:
- Acute flare-up support.
- Formulated with celery seed extract and Bosewellin super.
- Non-GMO and gluten-free.
- Go-Out Extra Strength is designed for people who work toward healthy uric acid levels. The supplement contains a potent combination of tart cherry extract, celery seed extract, and Bosewellin super.
- Take 1 capsule twice a day with meals.
- Adults take 2 tablets per day and do not exceed 4 tablets per day.
Advertisement
Related to this article
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
What Pharmacists Should Know About Sea Buckthorn for Respiratory Health
4
FDA Grants Accelerated Approval to Ravulizumab for Proteinuria Reduction in IgA Nephropathy
5